Introduction
============

Inflammatory bowel diseases (IBDs) are characterized by inflammation and intestinal damage. The S100 proteins S100A8/A9 and S100A12 have been suggested to be useful for assessing disease activity and monitor treatment efficacy. S100A8/A9 is produced by granulocytes, monocytes and macrophages whereas S100A12 expression is restricted to granulocytes and may thus be more specific.

Aim
===

To develop an ELISA for fecal S100A12 and investigate its utility for the clinical investigation of patients with UC and CD.

Patients and methods
====================

The ELISA (Inflamark™, Cisbio bioassays) is based on 2 monoclonal antibodies raised against recombinant human S100A12. After stool extraction, S100A12 was measured in UC (n=30), CD (n=30) and healthy (n=30) subjects. Fecal S100A12 was correlated with the endoscopic Mayo score in subjects with UC and data were compared to fecal S100A8/A9.

Results
=======

Western blotting showed that the two antibodies selected for the ELISA recognized both recombinant and purified native human S100A12 and did not cross-react with S100A8/A9. Intra and inter assay precision errors were below 10%. Fecal S100A12 levels were significantly higher in UC (median: 167 μg/g stool, p\<0.0001) and CD (median 14 μg/g stool, p\<0.0001) patients than in healthy controls (median: 0), with a corresponding area under the ROC of 0.83 (p \<0.0001) and 0.71 (p\<.0001), in UC and CD, respectively. In patients with UC, fecal S100A12 correlated with the endoscopic Mayo score (r=0.48, p=0.0067) and levels were on average 24 fold higher in subjects presenting with active (n=16, Mayo score 2-3) than in patients with inactive (n=14, Mayo score 0-1) disease. The difference between active and non-active UC patients was lower (5.2 fold) for S100A8/9 than for S100A12 and did not reach statistical significance (p=0.067).

Conclusions
===========

The new ELISA for fecal S100A12 is precise and could detect increased inflammatory activity in patients with UC and CD. Measurements of fecal S100A12 should be useful for the non-invasive assessment of intestinal damage in patients with IBDs.
